Anticoagulation After Intracranial Hemorrhage and Stroke

Learn more about maximizing patients’ benefit from anticoagulation therapy and minimizing risk following intracranial hemorrhage and stroke.

Target Audience

Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Rehabilitation and Pain Management Specialists, Clinical Pharmacists, as well as other specialists interested in the field of neuroscience.

Learning Objectives

  • Analyze the pros and cons of anticoagulation following ICH or ischemic stroke.
  • Select patients who would benefit from early anticoagulation and determine the appropriate anticoagulation strategy with regard to timing of initiation and agents of choice.
Additional information
Bibliography: 
  • January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland Jr, J. C., ... & Murray, K. T. (2014). AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 130(23), e199-267.
  • January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Conti, J. B., ... & Sacco, R. L. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 64(21), e1-e76.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Course opens: 
02/01/2019
Course expires: 
01/31/2022

Kiwon Lee, M.D., FACP, FAHA, FCCM
Professor of Neurology
Chief of Neurology Service
Chief, Division of Stroke and Critical Care
Director, RWJ Comprehensive Stroke Center
Director, Neuro-Intensive Care Unit
Rutgers, The State University of New Jersey
Robert Wood Johnson Medical School
New Brunswick, N.J.

Kiwon Lee, M.D., faculty of this educational activity, has no relevant financial relationships with ineligible companies* to disclose and has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

PLANNING COMMITTEE

Kevin Abrams, M.D., indicated that he is a consultant and shareholder with Keystone Heart.

Guilherme Dabus, M.D., indicated that he is a consultant for Microvention/Terumo, Medtronic, Penumbra and Cerenovus, and on the speakers' bureau for Microvention/Terumo, Medtronic and Penumbra. He is a proctor for Medtronic. Dr. Dabus is also a shareholder with Surpass Medical/Stryker, Medina/Medtronic, InNeuro Co and Three Rivers Medical.

Daniel D’Amour, M.D., Felipe De Los Rios, M.D., Karel Fuentes, M.D., Sergio Gonzalez-Arias, M.D., Ph.D., Kunal Patel, M.S., Amy K. Starosciak, Ph.D., and Jayme Strauss, R.N., MSN, have no relevant financial relationships with ineligible companies* to disclose and have indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Bruno V. Gallo, M.D., indicated that he is on speakers bureau for Teva Pharmaceuticals and Sunovion Pharmaceuticals. He receives grant support for Medtronic International, Pfizer Pharmaceuticals, Glaxo-SmithKline and St. Jude Medical, Inc. Dr. Gallo serves as a consultant for Cyberonics, Teva Pharmaceuticals, St. Jude Medical, ONS Inc. and Sugimon LLC.

Italo Linfante, M.D., indicated that he is a consultant for Medtronic, Stryker and Penumbra. He is a stockholder with InNeuro Co.

Alberto Pinzon-Ardila, M.D., indicated that he is on the speakers' bureau for Sunovion Pharmaceuticals and UCB.

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Please login or register to take this course.

Required Hardware/software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.